Close
Identification of Protein and Genetic Biomarkers of Prostate Cancer and Risk Factors for Progression of Disease
The purpose of this study is to identify genetic variants that predict progression of prostate cancer.
A Phase 1, Multi-Center, Open-Label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Evidence of Antitumor Activity of INV-9956 in Adult Patients with Advanced Metastatic Castration Resistant Prostate Cancer
This is a Phase 1a, first-in-human, open-label dose-escalation study to determine the RDR and/or MTD, and to assess the DLT of INV-9956. The safety, tolerability, PK/PD, and preliminary antitumor activity of INV-9956 will be assessed in adult patients with advanced mCRPC.
An International Prospective Open-label, Multi-center, Randomized, non-comparative Phase II Study of lutetium (177Lu) vipivotide tetraxetan (AAA617) alone and lutetium (177Lu) vipivotide tetraxetan (AAA617) in combination with Androgen Receptor Pathway In
The purpose of this study is to evaluate the efficacy and safety of AAA617 alone (Lutetium [177Lu] vipivotide tetraxetan) and in combination with an Androgen Receptor Pathway Inhibitors (ARPI) in participants with PSMA-positive, castration-resistant prostate cancer and no evidence of metastasis in conventional imaging (CI) (i.e., CT/MRI and bone scans). Approximately 120 participants will be randomized.